市場調査報告書：遺伝子増幅技術

FACTS AT A GLANCE

Most comprehensive report covering worldwide markets
Data-intensive research - An imperative for the serious player!
Designed to empower the quality conscious executive
Presented in crisp easy-to-use tables, charts, and text formats
Research assisted and subscribed by many key players worldwide!

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

PCR Dominates Amplification Technologies II-1
Miniaturization - The Next Big Focus II-2
Gene Amplification Technology- Backbone of Human Genome Project II-2
Critical in Diagnostic Procedures II-2
Leading Players II-2

2. Technology Overview II-3

Definition of Gene Amplification II-3
Target vs. Signal Amplification II-3
Available Types of Gene Amplification Technologies II-3
Polymerase Chain Reaction II-3
Reagents and Equipment required for PCR II-4
Reaction Steps II-4
Denaturation II-4
Annealing II-4
Extension II-4
Detection of Amplified Product/DNA II-5
(Q&Q) PCR II-5
Novel PCR Methods II-6
LightCycler RT- PCR Systems II-6
Reverse Transcriptase PCR (RT-PCR) II-6
RT-PCR Enzymes II-6
Major companies offering RT-PCR Enzymes II-6
Alternative Technologies to PCR II-7
OmniPlex II-7
Genome-wide Disease Association Studies II-7
Pharmacogenomics Studies II-7
Molecular Diagnostics and Forensics II-7
Additional OmniPlex Applications in Development II-7
Strand Displacement Amplification II-7
Ligase Chain Reaction II-8
LCR Involves a Cyclic Two-Step Reaction II-8
Gene Amplification Technology (GAT) II-8
Hybrid Capture II-8
HC2 II-9
HC3 II-9
HC-EAS II-9
Advantages of HC technology II-10
Sensitivity II-10
Intra-Slide and Inter-Slide Reproducibility II-10
Isothermal DNA Amplification Techniques II-10
Rolling circle Amplification in Diagnostics II-10
Companies and Research Centers into RCA Diagnostics II-10
Basics of RCA in DNA Diagnostics II-10
Applications of RCA II-11
RCAT-immunodiagnostics II-11
Ican Isothermal Gene Amplification Technology II-11
Other Amplification Technologies II-12
Signal Amplification Technology II-12
Transcription Mediated Amplification II-12
DNA cleavage-based signal amplification II-12
Invader Technology From TWT II-12
Ramification Amplification Method II-12

3. End Use Market Analysis II-14

Medical and Diagnostics II-14
Role of Amplification Technology in Diagnostics of Infectious Diseases II-14
Diagnosis of Infectious Diseases by PCR II-14
Detection of Antimicrobial Resistance II-15
PCR Based Nucleic Acid Amplification for Detection of Antimicrobial Agents II-15
Nucleic Acid Amplification Testing (NAT) II-16
Nucleic Acid Amplification Methods Available in the Market II-16
The HCV RNA Testing II-16
Recent Patents in Nucleic Acid Amplification II-16
Sysmex Introduces New Gene Amplification Detection Technologies II-18
Advantages and Limitations of DNA Amplification Technology in the Diagnosis of Infectious Diseases II-18
Forensic and Paternity II-18
Food Safety II-19

4. Research and Development II-20

HC - More Precise Predictor than HercepTest II-20
ITF - Target of Gene Amplification in Melanoma II-20

5. Product Launches II-21

QIAGEN Rolls Out Wide RNAi and SYBRｮ
Green-based RT- PCR II-21
Applied Biosystems Launches 7500 Fast Real-Time PCR System II-21
Applied Biosystems Launches 9800 Fast PCR System II-21
7900HT Fast Real-Time PCR System from Applied Biosystems II-21
Enzo Life Sciences Introduces New Advanced Amplification Technology II-22
Applied Biosystems Unveils AmpFSTRｮ Yfiler・PCR Amplification Kit II-22
Sysmex Introduces GD-100 II-22
Amersham Launches GenomiPhi II-23
Rubicon Genomics Launches GenomePlex WGA II-23
Agilent Introduces Amplification Kit II-23
Linden Introduces Snapshot mRNA II-23
Rubicon Launches OmniPlex・II-23

6. Recent Industry Activity II-24

Sigma-Aldrich Acquires JRH II-24
Sigma-Aldrich Snaps Up Proligo II-24
Beckman to Acquire Agencourt II-24
Nanogen Inks Licensing Agreement with Pathway II-24
Nanogen Signs Agreement with decode II-24
Roche Diagnostics and Applera Corporation Expand PCR Licensing Program II-24
Nanogen Receives Patents II-25
Mount and Hamilton Receive Patent II-25
Invitrogen Bags License from Applied Biosystems II-25
Sanko Attains Patents II-25
Applied Imaging Obtains 510(k) Clearance from FDA II-25
OriGene to Access TrueClone II-25
Agilent to Offer Genomics in India II-26
Orchid BioSciences to Turn into Orchid Cellmark II-26
Spectral acquires Bacterial Barcodes II-26
QIAGEN Purchases Assets of Molecular Staging II-26
Sigma-Aldrich Partners Ingex II-26
Cepheid, Applied Biosystems and Celera Diagnostics Sign Patent License Agreement II-26
Abbott Enters into Agreement with BioGenex II-27
Roche Inks Licensing Agreement with Incyte Corp II-27
Rubicon Genomics Signs Licensing Agreement with Sigma-Aldrich II-27
BioM駻ieux Teams-up with Cepheid II-27
Molecular Staging Collaborates with Eli Lilly II-27
Pacific Biometrics Inc. Receives Gene Amplification Patent... II-27
Rubicon Introduces Service for Genome Amplification... II-28
Rubicon Provides Amplification Technology to Wellcome Trust II-28
Takara Obtains Patent for New Amplification Method II-28
Roche Signs Agreement with Qiagen GmbH II-28
Roche Diagnostics Strikes a Deal with Innogenetics N.V II-28
Idaho Receives Contract for PCR II-28
Nanosphere Signs Agreement with Takara II-28
Eiken Acquires US Patent II-29
Bio-Rad Laboratories Offers DNA Amplification Technology to Specialty Laboratories II-29
Vysis Obtains Registration for HER-2 Gene Amplification in Breast Cancer II-29
NIGMA Grants Award to Ambion for RNA
Amplification II-29
Molecular Staging Receives Three Patents for Rolling Circle Amplification Technology II-29
NuGEN Develops Ribi-SPIA・of RNA Amplification II-30
Phenix Research Products Launches DNA Amplification System... II-30
Takara Gains Exclusive Rights to Sell Gene Amplification Equipment from Cepheid II-30
Gene Tec's Licenses Gene Amplification Method to Applied Biosystems II-30
Incyte Awards License to Merck & Co II-30

7. Focus on Select Global Players II-31

Applied Biosystems (US) II-31
Abbott Laboratories (US) II-31
Vysis Inc (US). II-31
Bio Merieux (France) II-32
Biotecon Diagnostics (Germany) II-32
Bio-Rad Laboratories (US) II-32
Cepheid (US) II-33
Eppendorf (Germany) II-33
GE Healthcare (US) II-33
QIAGEN N.V (The Netherlands) II-34
Roche Diagnostics (Switzerland) II-34
Rubicon Genomics (US) II-35
Stratagene (US) II-35
Takara Shuzo co., Ltd. (Japan) II-35
Thermo Electron Molecular Biology (UK) II-36
Techne Inc (UK) II-36
Third Wave Technologies (US) II-36

8. Global Market Perspective II-37

Table 1: World Recent Past, Current & Future Market Analysis for Gene Amplification Technologies by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-37
Table 2: World 10-Year Perspective for Gene Amplification Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-37
Table 3: World Recent Past, Current & Future Market Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-38
Table 4: World 10-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-38
Table 5: World Recent Past, Current & Future Market Analysis for Other Gene Amplification Technologies by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-39
Table 6: World 10-Year Perspective for Other Gene Amplification Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-39

III. MARKET

1. The United States III-1

A. Market Analysis III-1
Focus on Key Players III-1
Abbott Laboratories III-1
Vysis Inc. III-1
Applied Biosystems III-2
Bio-Rad Laboratories III-2
Cepheid III-2
GE Healthcare III-3
ID Biomedical Corp., III-3
Rubicon Genomics III-3
Stratagene III-4
Third Wave Technologies III-4
Product Launches III-4
Strategic Developments III-7
B. Market Analytics III-14
Table 7: US Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-14
Table 8: US 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdownof Dollar Sales for Polymerase Chain Reaction (PCR)and Other Gene Amplification Marketsfor 2000, 2005 & 2010) III-14

2. Canada III-15

Market Analysis III-15
Table 9: Canadian Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-15
Table 10: Canadian 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase Chain Reaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-15

3. Japan III-16

A. Market Analysis III-16
Takara Shuzo Co., Ltd. - A Key Japanese Player III-16
Product Launch III-16
Strategic Developments III-16
B. Market Analytics III-17
Table 11: Japanese Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through2010 (includes corresponding Graph/Chart) III-17
Table 12: Japanese 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase Chain Reaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-17

4. Europe III-18

Market Analysis III-18
Table 13: European Recent Past, Current & Future Analysis for Gene Amplification Technologies by GeographicRegion - France, Germany, UK, Italy, and Rest of Europe Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-18
Table 14: European Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2000through 2010 (includes corresponding Graph/Chart) III-19
Table 15: European 10-Year Perspective for Gene Amplification Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, & Rest of Europe Marketsfor Years 2000, 2005 & 2010 (includescorresponding Graph/Chart) III-19
Table 16: European 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-20

4a. France III-21

A. Market Analysis III-21
Bio Merieux - A Key French Player III-21
B. Market Analytics III-22
Table 17: French Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2000through 2010 (includes corresponding Graph/Chart) III-22
Table 18: French 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-22

4b. Germany III-23

A. Market Analysis III-23
Focus on Select Players III-23
Eppendorf III-23
Biotecon Diagnostics III-23
B. Market Analytics III-24
Table 19: German Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2000through 2010 (includes corresponding Graph/Chart) III-24
Table 20: German 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-24

4c. United Kingdom III-25

A. Market Analysis III-25
Focus on Select Players III-25
Thermo Hybaid III-25
Techne Inc III-25
B. Market Analytics III-26
Table 21: UK Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-26
Table 22: UK 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets for 2000, 2005 & 2010 III-26

4d. Italy III-27

Market Analysis III-27
Table 23: Italian Recent Past, Current & Future Analysis for Gene Amplification Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000through 2010 (includes corresponding Graph/Chart) III-27
Table 24: Italian 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-27

4e. Rest of Europe III-28

A. Market Analysis III-28
Product Launch III-28
Focus on Key Players III-28
QIAGEN N.V (Netherlands) III-28
Roche Diagnostics (Switzerland) III-29
B. Market Analytics III-30
Table 25: Rest of Europe Market for Gene Amplification Technologies - Recent Past, Current & Future Market Analysis by Segment for Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual Sales Figures in US$ Millionfor Years 2000 through 2010 (includescorresponding Graph/Chart) III-30
Table 26: Rest of Europe 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-30

5. Rest of World III-31

Market Analysis III-31
Table 27: Rest of World Market for Gene Amplification Technologies - Recent Past, Current & Future Market Analysis by Segment for Polymerase Chain Reaction (PCR) and Other Gene Amplification Markets Independently Analyzed with Annual Sales Figures in US$ Millionfor Years 2000 through 2010 (includescorresponding Graph/Chart) III-31
Table 28: Rest of World 10-Year Perspective for Gene Amplification Technologies by Segment - Percentage Breakdown of Dollar Sales for Polymerase ChainReaction (PCR) and Other Gene AmplificationMarkets for 2000, 2005 & 2010 III-31

IV. COMPETITION

1. Abbott Laboratories (USA) IV-1
Table 29: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-4
Table 30: Annual Sales Analysis: 2003-2004 (In US$ billion) IV-4
Table 31: Quarterly Sales Analysis: 2003-2004 (In US$ billion) IV-4
Table 32: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion) IV-4
Table 33: Annual sales Analysis by Geographical Region: 2003-2004 (In US$ billion) IV-4
Vysis, Inc. (USA) IV-9
2. ABgene (UK) IV-13
3. Advanced Biotechnologies, Inc.
4. Agilent Technologies, Inc. (USA) IV-15
5. Agilent Technologies, Inc. (USA) IV-17
Table 34: Quarterly Sales Analysis: 2004- 2005 (Q1) (In US$ million) IV-19
Table 35: Quarterly Sales Analysis by Segment: 2004-2005 (Q1) (In US$ million) IV-20
Table 36: Annual Sales Analysis by Geographical Region: 2004-2005 (Q1) (In US$ million) IV-20
Table 37: Annual Sales Analysis: 2003-2004 (In US$ million) IV-20
Table 38: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million) IV-20
Table 39: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-21
Table 40: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million) IV-21
6. Ambion, Inc. (USA) IV-55
7. Applera Corporation (USA) IV-57
Table 41: Annual Sales Analysis by Operation: 2004-2005 (Nine Months Ended March) (In US$ million) IV-58
Table 42: Annual Sales Analysis: 2003-2004 (In US$ million) IV-58
Table 43: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-58
Table 44: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-59
Table 45: Annual Sales Analysis by Operation: 2003-2004 (In US$ million) IV-59
Table 46: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-59
8. Applied Biosystems (USA) IV-60
Table 47: Annual Sales Analysis: 2003-2005 (In US$ million) IV-61
Table 48: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-61
Table 49: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-61
Table 50: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-61
9. Aptagen, Inc. (USA) IV-69
10. ATG Laboratories, Inc. (USA) IV-70
11. Athersys, Inc. (USA) IV-71
12. BioCat GmbH (Germany) IV-73
13. BioGenex Laboratories, Inc. (USA) IV-74
14. bioMerieux SA (France) IV-80
Table 51: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In € million) IV-80
Table 52: Nine Months Sales Analysis by Geographic Region: 2004-2005 (Nine Months Ended, September) (In € million) IV-81
Table 53: Nine Months Sales Analysis by Segment: 2004-2005 (Nine Months Ended, September) (In € million) IV-81
Table 54: Annual Sales Analysis: 2003-2004 (In € million) IV-81
Table 55: Annual Sales Analysis by Product Segment: 2003-2004 (In € million) IV-81
15. Bio-Rad Laboratories, Inc. (USA) IV-85
Table 56: Quarterly Sales Analysis: 2004-2005 (Q1) (In US$ million) IV-86
Table 57: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-86
16. Bio-Synthesis, Inc. (USA) IV-91
17. Biotecon Diagnostics GmbH (Germany) IV-92
18. Biotools, B and M Labs SA (Spain) IV-93
19. BT&C, INC. / OPS Diagnostics LLC (USA) IV-94
20. Caliper Technologies Corporation (USA) IV-95
21. Cambio Limited (UK) IV-98
22. Cambrex Bio Science Rockland, Inc. (USA) IV-101
23. Cepheid, Inc. (USA) IV-102
Table 58: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-103
Table 59: Annual Sales Analysis: 2003-2004 (In US$ million) IV-103
24. Charles River Laboratories, Inc. (USA) IV-105
25. Chromos Molecular Systems, Inc. (Canada) IV-106
26. Chugai Pharmaceutical Co., Ltd. (Japan) IV-107
Table 60: Annual Sales Analysis: 2003-2004 (In ¥ million) IV-108
27. Complement Genomics Limited (UK) IV-111
28. Copernicus Therapeutics, Inc. (USA) IV-113
29. Covance, Inc. (USA) IV-114
30. Cytomyx Limited (UK) IV-116
31. CytRx Corporation (USA) IV-117
32. Dakocytomation (USA) IV-118
33. Diatech Srl (Italy) IV-120
34. Digene Corporation (USA) IV-121
Table 61: Annual Sales Analysis: 2003-2005 (In US$ million) IV-121
Table 62: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million) IV-122
Table 63: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-122
35. Discovery Partners International, Inc. (USA) IV-124
36. Diversa Corporation (USA) IV-126
37. Durviz Sl (Spain) IV-128
38. Dynal Biotech Asa (Norway) IV-129
39. Edge Biosystems, Inc. (USA) IV-131
40. Eiken Chemical Co., Ltd. (Japan) IV-132
41. Enzo Life Sciences, Inc. (USA) IV-133
42. Epicentre Technologies Corporation (USA) IV-134
43. Epoch Biosciences, Inc. (USA) IV-142
44. Eppendorf AG (Germany) IV-143
Table 64: Annual Sales Analysis: 2003-2004 (In € million) IV-144
45. Eragen Biosciences Inc. (USA) IV-149
46. Exiqon A/S (Denmark) IV-150
47. ExpressOn Biosystems (UK) IV-151
48. Fermentas AB (Lithuania) IV-152
49. Finnzymes Oy (Finland) IV-154
50. GE Healthcare (USA) IV-155
51. Gene Tec Corporation (USA) IV-182
52. Geneblitz (UK) IV-182
53. Genelabs Technologies Inc. (USA) IV-183
54. Genelex Corporation (USA) IV-184
55. Genhunter Corporation (USA) IV-185
56. Genisphere 3DNA/Genisphere, Inc. (USA) IV-189
57. Genolife SA (France) IV-190
58. Gen-Probe, Inc. (USA) IV-192
Table 65: Annual Sales Analysis: 2003-2004 (In US$ million) IV-192
59. Hamilton Thorne Biosciences (USA) IV-197
60. Helena Biosciences (UK) IV-198
61. HiberGen Limited (Ireland) IV-198
62. Icoria, Inc. (USA) IV-199
Table 66: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-200
Table 67: Half-Yearly Sales Analysis by Business Segment: 2004-2005 (H1) (In US$ million) IV-200
Table 68: Annual Sales Analysis: 2003-2004 (In US$ million) IV-200
Table 69: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-200
63. ID Biomedical Corporation (Canada) IV-204
Table 70: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-204
Table 71: Half-Yearly Geographical Sales Analysis: 2004-2005 (Six Months Ended) (In US$ million) IV-205
Table 72: Annual Sales Analysis: 2003-2004 (In US$ million) IV-205
Table 73: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-205
64. Idaho Technology, Inc. (USA) IV-207
65. Infectio Diagnostic, Inc. (Canada) IV-208
66. Invitrogen Corporation (USA) IV-209
Table 74: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-210
Table 75: Annual Sales Analysis: 2003-2004 (In US$ million) IV-210
Table 76: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-210
67. IVS Technologies LLC (USA) IV-215
68. KamTek, Inc. (USA) IV-216
69. Lark Technologies (UK) IV-217
70. Lgc Ltd. (UK) IV-218
71. Lifecodes Corporation (USA) IV-219
72. Maxim Biotech, Inc. (USA) IV-221
73. Microzone Limited (UK) IV-222
74. Molecular Bioproducts, Inc. (USA) IV-223
75. Molecular Sensing PLC (UK) IV-226
76. Molecular Staging, Inc. (USA) IV-227
77. MP Biomedicals (USA) IV-228
78. MWG-Biotech AG (Germany) IV-230
79. Nanogen, Inc. (USA) IV-235
80. New England Biolabs (UK) Ltd. (UK) IV-236
81. Norgen Biotek Corporation (Canada) IV-237
82. NuGEN Technologies, Inc. (USA) IV-240
83. Orchid BioSciences, Inc. (USA) IV-242
84. Origene Technologies, Inc. (USA) IV-246
85. PerkinElmer, Inc. (USA) IV-250
PerkinElmer Life Sciences, Inc. (USA) IV-255
86. Primagen BV (The Netherlands) IV-258
87. Proligo LLC (USA) IV-259
88. Promega Corporation (USA) IV-260
89. Qbiogene, Inc. (USA) IV-261
90. Qiagen NV (The Netherlands) IV-263
Table 77: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-263
Table 78: Annual Sales Analysis: 2003-2004 (In US$ million) IV-264
Table 79: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-264
Qiagen AG (Switzerland) IV-271
Qiagen GmbH (Germany) IV-271
Qiagen, Inc. (USA) IV-272
Qiagen Ltd. (UK) IV-272
Qiagen Pty, Ltd. (Australia) IV-273
Qiagen SA (France) IV-273
91. Research Biolabs Pte., Ltd. (Singapore) IV-274
92. RNAture, Inc. (USA) IV-274
93. Roche Diagnostics (Switzerland) IV-275
Table 80: Annual Sales Analysis: 2003-2004 (In SWF billion) IV-276
Roche Diagnostics Corporation (USA) IV-280
Roche Diagnostics, Ltd. (UK) IV-280
94. Rubicon Genomics (USA) IV-282
95. Seqwright, Inc. (USA) IV-284
96. Seracare Life Sciences, Inc. (USA) IV-285
Table 81: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, June) (In US$ million) IV-287
Table 82: Nine Months Sales Analysis by Division: 2004-2005 (Nine Months Ended, June) (In US$ million) IV-287
Table 83: Annual Sales Analysis: 2003-2004 (In US$ million) IV-287
Table 84: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-287
Table 85: Sales Analysis by Division: 2003-2004 (In US$ million) IV-287
Table 86: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-288
97. Sigma-Genosys Ltd. (UK) IV-290
98. Sooner Scientific, Inc. (USA) IV-298
99. Stratagene, Inc. (USA) IV-300
Table 87: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ Million) IV-301
Table 88: Annual Sales by Geographical Regions: 2003-2004 (In US$ Million) IV-301
100. Sysmex Corporation (Japan) IV-309
Table 89: Annual Sales Analysis: 2004-2005 (In ¥ million) IV-310
Table 90: Annual Sales by Geographical Regions: 2005-2004 (In ¥ million) IV-310
101. Takara Bio, Inc. (Japan) IV-317
Takara Bio Europe SA (France) IV-319
102. Techne, Inc. (USA) IV-320
Techne (Cambridge) Ltd. (UK) IV-324
103. Thermo Electron Corporation (USA) IV-325
Table 91: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-326
Table 92: Annual Sales Analysis: 2003-2004 (In US$ billion) IV-326
Table 93: Quarterly Sales Analysis: 2003-2004 (In US$ billion) IV-326
Table 94: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion) IV-327
Table 95: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ billion) IV-327
Thermo Electron Molecular Biology (UK) IV-338
104. Third Wave Technologies, Inc. (USA) IV-339
105. U.S. Genomics (USA) IV-340
106. Vaudaux-Eppendorf AG (Switzerland) IV-341
107. Vector-Best (Russia) IV-343
108. Viennalab Labordiagnostika GmbH (Austria) IV-344
109. Xtrana, Inc. (USA) IV-345

遺伝子増幅技術動向

Gene Amplification Technologies

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

2. Technology Overview II-3

3. End Use Market Analysis II-14

4. Research and Development II-20

5. Product Launches II-21

6. Recent Industry Activity II-24

7. Focus on Select Global Players II-31

8. Global Market Perspective II-37

III. MARKET

1. The United States III-1

2. Canada III-15

3. Japan III-16

4. Europe III-18

4a. France III-21

4b. Germany III-23

4c. United Kingdom III-25

4d. Italy III-27

4e. Rest of Europe III-28

5. Rest of World III-31

IV. COMPETITION